Due to the predominant humoral pathogenic mechanisms, it seems rationale to treat MOG antibody associated demyelination with immune suppression including steroids, plasma exchange, or a B-cell-directed therapy, similar to NMO [52, 53]. Here, MOG is linked to neuromyelitis optica.